A Phase 2 interventional study of Cetuximab and Oxaliplatin in Neoplasm Metastasis and Colorectal Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 78 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-07.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing cetuximab in Neoplasm Metastasis — 4 open to participants now, 4 under way, none of them phase 3. Cetuximab · Neoplasm Metastasis.
Among the 44 studies testing cetuximab in Neoplasm Metastasis, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 33 in phase 2, and was the 4th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.
Browse Neoplasm Metastasis studies →4 of the 44 studies testing cetuximab in Neoplasm Metastasis are open now, in 1 country. Recruiting first, the newest first:
Tongji Hospital · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18–75
Fujian Cancer Hospital
Ages 18–75
Liaoning Cancer Hospital & Institute
Ages 18–80
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 34 · Phase 3 4 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 344 is above the median of 50 across 3,275 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 64 across the 44 interventional studies. Of the 30 that completed or were terminated, 14 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 44 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 21 finished, 11 (52%) have results posted.
Among the 21 studies in Neoplasm Metastasis by Merck KGaA, Darmstadt, Germany, this one is the 3rd largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2005, is one of 3 in phase 2, and was the 1st registered.
Merck KGaA, Darmstadt, Germany’s Neoplasm Metastasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing cetuximab in Neoplasm Metastasis, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 21 in Neoplasm Metastasis:
This tab as a report to print or save as PDF → With an account.
This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor (EGFR)-expressing mCRC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Cetuximab
Drug: Oxaliplatin
Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m\^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops
Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m\^2/day IV over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops
Best Overall Response Rate - Independent Review Committee (IRC)
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified World Health Organisation (WHO) criteria) as assessed by an IRC.
Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
Best Overall Response Rate (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population)
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC.
Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
Best Overall Response Rate (KRAS Mutant Population)
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC.
Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
Progression-free Survival Time
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
Progression-free Survival Time (KRAS Wild-Type Population)
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
Progression-free Survival Time (KRAS Mutant Population)
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
Time frame: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
Overall Survival Time
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
Overall Survival Time (KRAS Wild-Type Population)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
Overall Survival Time (KRAS Mutant Population)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
Participants With No Residual Tumor After Metastatic Surgery
No residual tumor after on-study surgery for metastases.
Time frame: Time from first dose up to 30 days after the last dose of study treatment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
Disease Control Rate (Cut Off Date 4 August 2006)
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments as assessed by IRC (based on modified WHO criteria).
Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
Duration of Response
Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.
Time frame: Time from first assessment of Complete Response or Partial Response to disease progression,death or last tumor assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
Safety - Number of Patients Experiencing Any Adverse Event
Please refer to Adverse Events section for further details
Time frame: time from first dose up to 30 after last dose of study treatment, reported between day of first patient dose of study treatment, 27 Jul 2005, until cut-off date 30 Nov 2008
First \& last subject randomized: 27 Jul 2005 \& 8 Mar 2006, respectively. Primary outcome and disease control rate cut-off dates 4 Aug 2006, others: 1 Mar 2007; except overall survival, KRAS overall survival and KRAS progression-free survival outcomes, metastatic surgery outcome and adverse events: 30 Nov 2008.
| Milestone | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Started | 170 | 168 |
| Completed | 170 | 168 |
| Not completed | 0 | 0 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified World Health Organisation (WHO) criteria) as assessed by an IRC.
| percentage of participants | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Best Overall Response Rate - Independent Review Committee (IRC) | 45.6 (37.9 to 53.4) | 35.7 (28.5 to 43.5) |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC.
| percentage of participants | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Best Overall Response Rate (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) | 57.3 (45.9 to 68.2) | 34.0 (24.7 to 44.3) |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC.
| percentage of participants | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Best Overall Response Rate (KRAS Mutant Population) | 33.8 (23.4 to 45.5) | 52.5 (39.1 to 65.7) |
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Progression-free Survival Time | 7.2 (5.6 to 7.7) | 7.2 (6.0 to 7.8) |
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Progression-free Survival Time (KRAS Wild-Type Population) | 8.3 (7.2 to 12.0) | 7.2 (5.6 to 7.4) |
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Progression-free Survival Time (KRAS Mutant Population) | 5.5 (4.0 to 7.3) | 8.6 (6.5 to 9.4) |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
| months | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Overall Survival Time | 18.3 (14.8 to 20.4) | 18.0 (16.7 to 21.8) |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
| months | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Overall Survival Time (KRAS Wild-Type Population) | 22.8 (19.3 to 25.9) | 18.5 (16.4 to 22.6) |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
| months | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Overall Survival Time (KRAS Mutant Population) | 13.4 (10.5 to 17.7) | 17.5 (14.7 to 24.8) |
No residual tumor after on-study surgery for metastases.
| participants | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Participants With No Residual Tumor After Metastatic Surgery | 8 | 4 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments as assessed by IRC (based on modified WHO criteria).
| percentage of participants | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Disease Control Rate (Cut Off Date 4 August 2006) | 85.2 (78.9 to 90.2) | 81.0 (74.2 to 86.6) |
Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.
| months | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Duration of Response | 9.0 (5.9 to 11.1) | 5.7 (5.4 to 7.7) |
Please refer to Adverse Events section for further details
| participants | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| Safety - Number of Patients Experiencing Any Adverse Event | 170 | 165 |
Collected over Time from first dose up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab Plus FOLFOX-4 | — | 61/170 (35.9%) | 170/170 (100%) |
| FOLFOX-4 Alone | — | 43/168 (25.6%) | 165/168 (98.2%) |
| Event | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 4/170 | 5/168 |
| HYPERSENSITIVITYImmune system disorders | 5/170 | 2/168 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 5/170 | 2/168 |
| VOMITINGGastrointestinal disorders | 2/170 | 4/168 |
| PYREXIAGeneral disorders | 4/170 | 4/168 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 4/170 | 3/168 |
| ILEUSGastrointestinal disorders | 4/170 | 1/168 |
| PNEUMONIAInfections and infestations | 3/170 | 3/168 |
| LEUKOPENIABlood and lymphatic system disorders | 3/170 | 2/168 |
| INTESTINAL OBSTRUCTIONGastrointestinal disorders | 3/170 | 0/168 |
| Event | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone |
|---|---|---|
| RASHSkin and subcutaneous tissue disorders | 90/170 | 4/168 |
| NEUTROPENIABlood and lymphatic system disorders | 77/170 | 84/168 |
| DIARRHOEAGastrointestinal disorders | 81/170 | 68/168 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 45/170 | 69/168 |
| NAUSEAGastrointestinal disorders | 69/170 | 65/168 |
| FATIGUEGeneral disorders | 54/170 | 43/168 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 46/170 | 51/168 |
| LEUKOPENIABlood and lymphatic system disorders | 49/170 | 43/168 |
| VOMITINGGastrointestinal disorders | 48/170 | 37/168 |
| ANAEMIABlood and lymphatic system disorders | 44/170 | 41/168 |
| Age, Categorical(Participants) | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 96 | 109 | 205 |
| >=65 years | 73 | 59 | 132 |
| Age, Continuous(years) | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone | Total |
|---|---|---|---|
| Median | 62.0 (24 to 82) | 60.0 (30 to 82) | 61.0 (24 to 82) |
| Sex: Female, Male(Participants) | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone | Total |
|---|---|---|---|
| Female | 80 | 76 | 156 |
| Male | 89 | 92 | 181 |
| Region of Enrollment(participants) | Cetuximab Plus FOLFOX-4 | FOLFOX-4 Alone | Total |
|---|---|---|---|
| Portugal | 0 | 3 | 3 |
| Spain | 19 | 16 | 35 |
| Ukraine | 24 | 25 | 49 |
| Austria | 16 | 9 | 25 |
| Russian Federation | 25 | 24 | 49 |
| Israel | 0 | 1 | 1 |
| Italy | 8 | 6 | 14 |
| France | 3 | 12 | 15 |
| Belgium | 12 | 6 | 18 |
| Poland | 30 | 31 | 61 |
| Romania | 18 | 13 | 31 |
| Germany | 14 | 22 | 36 |
The record gives a start of Jul 2005, a primary completion of Mar 2007 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab
Merck KGaA, Darmstadt, Germany →